Curative Biotech

Curative Biotechnology is a development-stage company with research efforts centered around identifying and developing disease-modifying therapeutic drug candidates for rare disease indications. Their pipeline includes ongoing programs in three key areas: degenerative eye disease (The company is developing a Metformin reformulation for age-related macular degeneration), infectious disease (the synthetic molecule, IMT504, to treat symptomatic rabies), and neuro-oncology (monoclonal antibody). Curative Biotech's approach involves acquiring and developing promising therapeutic drug candidates with a focus on accelerated development pathways.

Jobs:

News: